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Abstract 
Objectives: To investigate the functional effect of genetic polymorphisms of the inflammatory 
pathway on structural extracellular matrix components (ECM) and the susceptibility to an 
anterior cruciate ligament (ACL) injury.  
Design: Laboratory study, case-control study  
Method: Eight healthy participants were genotyped for interleukin (IL)1B rs16944 C>T and IL6 
rs1800795 G>C and classified into genetic risk profile groups. Differences in type I collagen 
(COL1A1), type V collagen (COL5A1), biglycan (BGN) and decorin (DCN) gene expression 
were measured in fibroblasts either unstimulated or following IL-1β, IL-6 or tumor necrosis 
factor (TNF)-α treatment.  
Moreover, a genetic association study was conducted in: (i) a Swedish cohort comprised of 
116 asymptomatic controls (CON) and 79 ACL ruptures and (ii) a South African cohort of 100 
CONs and 98 ACLs. Participants were genotyped for COL5A1 rs12722 C>T, IL1B rs16944 
C>T, IL6 rs1800795 G>C and IL6R rs2228145 G>C.  
Results: IL1B high-risk fibroblasts had decreased BGN (p=0.020) and COL5A1 (p=0.012) 
levels after IL-1β stimulation and expressed less COL5A1 (p=0.042) following TNF-α 
treatment. Similarly, unstimulated IL6 high-risk fibroblasts had lower COL5A1 (p=0.012) levels 
than IL6 low-risk fibroblasts.  
In the genetic association study, the COL5A1-IL1B-IL6 T-C-G (p=0.034, Haplo-score 2.1) and 
the COL5A1-IL1B-IL6R T-C-A (p=0.044, Haplo-score: 2.0) combinations were associated with 
an increased susceptibility to ACL injury in the Swedish cohort when only male participants 
were evaluated.  
Conclusion: This study shows that polymorphisms within genes of the inflammatory pathway 
modulate the expression of structural and fibril-associated ECM components in a genetic risk 
depended manner, contributing to an increased susceptibility to ACL injuries.  
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Introduction 
One of the most common knee injuries include the anterior cruciate ligament (ACL) rupture. 
The ability of the ACL to maintain its extracellular matrix (ECM) integrity is critical to its function 
to effectively resist mechanical loads and prevent injury1. Loading activates matrix-remodeling 
pathways to maintain ECM homeostasis, such as the inflammatory pathways (Figure 1). 
Therefore, it is not surprising that polymorphisms within these pathways contribute to the 
susceptibility of ACL injuries2, 3.  
Type V collagen is a functionally important collagen for the maintenance of tissue 
structure and integrity. The major isoforms consists of two α1 (V) and one α2 (V) chains 
encoded by COL5A1 and COL5A2 respectively4. Polymorphisms within the 3’UTR of COL5A1 
were previously implicated in ACL rupture5, 6 and tendinopathy5, 7. In addition, polymorphisms 
within genes encoding the α1(I) chain of type I collagen (COL1A1)8, biglycan (BGN)9 and 
decorin (DCN)9 were associated with ACL injury susceptibility. Together, these molecules form 
the basic building blocks of the ECM and are involved in collagen fibrillogenesis.  
Interleukin (IL) -1β is a pro-inflammatory cytokine encoded by IL1B and up-regulates 
the production of matrix metalloproteinases, regulating the degradation of specific ECM 
components, such as collagen types V and X10, 11. In addition, IL-1β induces its own expression 
and the expression of other pro-inflammatory cytokines such IL-6 (Figure 1)11. The C-allele of 
the IL1B promoter polymorphism rs16944 C>T increases IL-1β mRNA expression levels12 and 
is hypothesised to increase susceptibility to tendinopathy and ACL injury13, 14. 
IL6 is known to induce apoptosis15 and increase IL6 gene expression as seen with the 
G-allele of the IL6 rs1800795 G>C polymorphism16, would potentially be associated with 
increased risk for ligament injuries. IL-6 needs to bind and form complexes with the interleukin-
6 receptor (IL-6R) in order to exert its biological function. IL-6R exists as two isoforms: a 
membrane-bound receptor and a soluble receptor. IL6R rs2228145 A>C is located in the 
cleavage site and is thought to affect cleavage efficiency. Therefore, we hypothesize that the 
IL6R rs2228145 AA genotype is associated with an increased susceptibility to ligament injury.  
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Although currently no genetic loci within the gene encoding tumor necrosis factor α 
(TNF-α) have been associated with either ACL injuries or tendinopathies, this pro-inflammatory 
protein is considered to be key in the inflammatory pathway17. The biological function of TNF-
α is executed after binding to its receptor, the tumor necrosis factor receptor superfamily 
member 1A (TNFRSF1A). Similar to IL-6, TNF-α is involved in apoptosis and thereby possibly 
contributes to matrix remodeling capacity17.  
The main aim of the current study was to investigate the effects of specific genetic loci 
within the inflammatory pathway on the production of ECM components in an injury risk model. 
Additionally, the association of these genetic loci with susceptibility to ACL injury was 
evaluated in two independent populations of different ancestry. Based on the a priori 
hypothesis it was proposed that the IL1B rs16944 CC and the IL6 rs1800795 GG downregulate 
the production of ECM components and should therefore be associated with an increased 
susceptibility to ligament injuries.  
Methods 
All participants completed questionnaires regarding personal details, medical history, sporting 
history and a family history of tendon and ligament injury. Written informed consent was 
obtained from all participants according to the Declaration of Helsinki. Ethics approval was 
attained from the Human Research Ethics Commission (HREC) of Faculty of Health Sciences, 
University of Cape Town, South Africa (HREC 164/2006 and 645/2014) and the Regional 
Ethical Review Board in Umeå, Sweden (dnr. 2011-200-31M), where relevant. 
 
Participants 
In vitro study: Eight healthy, unrelated South African participants of self-reported Caucasian 
ancestry with no history of musculoskeletal soft tissue injuries were recruited. Venous blood 
and skin biopsies were taken from each participant. 
Swedish cohort: 195 physically active and unrelated participants (age 19-65 years) were 
recruited between 2011 and 2013 from either the Västerbotten or Norrbotten regions of 
Sweden, via the orthopedic clinics in two major hospitals in the cities of Umeå: Västerbotten 
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and Luleå: Norrbotten. Majority participants were recruited from a long term follow up of ACL 
injury18. This cohort consisted of 79 participants with ACL rupture (SWE-ACL) and 116 
asymptomatic participants without any history of ACL or tendon injury (SWE-CON). ACL 
ruptures were diagnosed based on physical examination, magnetic resonance imaging and 
arthroscopically confirmed at the University hospital in Umeå. Mechanism of injury data was 
categorized into direct contact, indirect contact, non-contact and skiing sports as previously 
defined6. All 79 cases reported a non-contact mechanism (SWE-NON) of injury. 
South African cohort: 198 physical active and unrelated participants were recruited from South 
Africa as previously described19. This cohort comprised of 100 asymptomatic controls (SA 
CON) and 98 participants with an ACL rupture (SA ACL) of which 51 reported a non-contact 
mechanism of injury.  
 
 
Genotyping 
A previously described protocol with slight modifications20 was used to extract genomic DNA 
from venous blood. Participants participating in the in vitro study were genotyped for the IL1B 
rs16944 C>T and IL6 rs1800795 G>C polymorphisms. Restriction fragment length 
polymorphism (RFLP) analysis was used for IL1B rs16944 (AvaI)14 while custom designed 
fluorescence-based Taqman PCR assays (Applied Biosystems, Foster City, CA, USA) were 
used to genotype IL6 rs1800795. Based on their genotypes, participants were either classified 
in the high-risk or low-risk profile group.  
Participants for the genetic association study were additionally screened for 
COL5A1 rs12722 C>T and IL6R rs2228145 A>C. All samples in the Swedish (n=195) and the 
South African cohort (n=198) were genotyped for the four SNPs using standard genotyping 
protocols. Restriction fragment length polymorphism (RFLP) analysis was used for the 
COL5A1 rs12722 (BstuI), and IL6R rs2228145 (HindIII) SNPs. All single nucleotide 
polymorphisms (SNPs): COL5A1 rs12722 C>T, IL1B rs16944 C>T, IL6 rs1800795 G>C and 
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IL6R rs2228145 A>C were selected based on their previously reported genetic associations 
with risk of ACL ruptures and Achilles tendinopathy2, 3. 
 
Fibroblast culture and treatment 
To establish primary fibroblast cultures, skin biopsies were processed according to a modified 
Baumgarten protocol21. Human dermal fibroblasts were cultured to 70% confluency in 
Dulbecco’s modified Eagle medium (DMEM, Gibco, Carlsbad, CA, USA) with 200 units/mL 
penicillin, 100 μg/mL streptomycin, 3.97 mM GlutaMAX (Gibco) and 10% FBS. Cells were 
serum-starved for 8h in DMEM and subsequently treated with 10ng/ml human recombinant 
(hr) IL622, 20ng/ml hrIL-1β23 or 10ng/ml hrTNF-α22 (all from Peprotech, Rocky Hills, NJ, USA). 
After 24h, cells were washed twice in ice-cold Dulbecco’s phosphate-buffered saline (DPBS, 
Sigma-Aldrich, Saint Louis, Missouri, USA) and frozen at -80°C until ready for RNA extraction, 
using the RNAeasy kit (Qiagen, Venlo, The Netherlands). Subsequently, a cDNA synthesis kit 
including a recombinant RNAse inhibitor (Thermo Scientific) using oligo (dT)s as primers was 
used. 
 
Real time RT-PCR 
A SYBR green-based buffer (Thermo Scientific), 10ng of cDNA, and primers specific for the 
transcript of interest, to a final concentration of 500nM each were mixed. PCR cycles were as 
follows: (2’30’’ at 50°C: 2’30’’ at 95°C) X1, (15’’ at 95°C: 30’’ at 60°C) X50 followed by melt-
curve analysis (95°C-60°C-95°C).  Real time RT-PCR analyses were performed using a 
Quantstudio3 real-time PCR machine (Thermo Scientific). The mRNA expression levels of 
structural matrix components, such as COL5A1, COL1A1, DCN and BGN were assessed for 
each sample including components of the inflammatory pathway, namely IL1B, IL6R1, IL6, 
IL6R and TNFRSF1A (Invitrogen, Carlsbad, CA, USA) (Supplementary Table 1). Cofilin 
(Invitrogen) was previously found stable and linearly correlated with RNA quantity (data not 
shown), and was therefore used as the housekeeping gene.  
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Statistics 
Statistical analyses were performed with the programming environment R (R Development 
Core Team). In the cytokine stimulation experiments, statistics were performed using 
Unpaired, two-tailed Student’s t-test. Power analysis was performed using QUANTO v.1.2.4 
(http://biostats.usc.edu/software) to calculate sample size for the Swedish cohort. Assuming 
minor allele frequencies between 0.1 and 0.5 a sample size of 79 cases would be adequate to 
detect an allelic odds ratio (OR) of 2.3 and greater at a power of 80%. Basic descriptive 
statistics were compared using the one-way analysis of variance to detect significant 
differences between characteristics of the SWE-CON group and the SWE-NON group. The R 
package genetics24 and SNPassoc25 were used to analyse differences in genotype and allele 
frequencies between the groups and to calculate Hardy-Weinberg equilibrium probabilities. 
Inferred allele constructs were created for COL5A1-IL1B-IL6-IL6R genes from both the 
Swedish and South African genotype data respectively using the haplo.stats package in R26. 
The analysed models were based on previously reported associations13, 14.  
 
Results 
Basal mRNA levels of high-risk vs. low-risk fibroblasts 
Fibroblasts derived from 8 donors had a high-risk genetic profile for either IL1B rs16944 C>T 
or IL6 rs1800795 G>C (Supplementary Table 2). All other donors who did not meet these two 
genetic risk profiles were excluded from further analysis. No significant differences in basal 
expression were observed in any of the ECM genes when fibroblasts were classified based on 
IL1B genotypes (Figure 2A). A reduced (p=0.012) COL5A1 expression was noted in IL6-high-
risk fibroblasts compared to low-risk fibroblasts. As for the cytokine-related genes, we found 
that TNFRSF1A was less (p=0.003) expressed in the untreated IL6-high-risk fibroblasts. 
(Supplementary Figure 1A, B).  
 
Response to cytokine stimulation by high-risk vs. low-risk fibroblasts 
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In IL1B-high-risk fibroblasts, COL5A1 (p=0.012) and BGN (p=0.020) expression were reduced 
following hrIL-1β. Additionally, treatment with hrTNF-α resulted in decreased COL5A1 
(p=0.042) levels (Figure 2C). In untreated IL6 high-risk fibroblasts, COL5A1 was reduced 
(p=0.012) compared to IL6 low-risk fibroblasts (Figure 2B). No Stimulation of the fibroblasts 
with hrIL-6  (Supplementary Figure 1C, D), hrIL-1β  (Supplementary Figure 1E, F) or hrTNF-
α (Supplementary Figure 1G, H) did not significantly alter the expression of any of the 
cytokine-related genes analysed. 
 
 
 
 
 
 
Case control genetic association study 
Polymorphisms within IL1B and IL6 alter the expression of structural and fibril-associated ECM 
components and herewith possibly modulate the susceptibility of ligament injuries. Therefore, 
these associations were further investigated in other population groups from (i) Sweden and 
(ii) an indigenous mixed ancestry population from South Africa. 
 
Participants 
The South African population was previously described in detail19. Swedish participants were 
matched for height, body mass and body mass index (BMI) (Supplementary Table 3). 
However, participants in the SWE-CON group consisted of significantly less men (34.5%, 
n=40) than the SWE-NON group (54.4%, n=43, p=0.014) and were significantly older (44.7 ± 
11.9, n=114) than participants in the SWE-NON group (36.5 ± 13.7, n=78, p<0.001). 
Differences in medical and family history are displayed in Supplementary Table 4. No 
significant genotype effects were noted on age, sex, height, body mass or body mass index 
for the investigated polymorphisms (Supplementary Table 5). 
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Genotype and allele frequency distributions 
No significant differences in genotype or allele frequency distributions were observed for either 
COL5A1 rs12722 C>T, IL1B rs16944 C>T and IL6 rs1800795 G>C in both the South African 
and Swedish cohorts (Table 1). However, for the South African cohort the IL6R rs2228145 
A>C CC genotype was significantly overrepresented (p= 0.028) in the SA-CON group (13%, 
n=12) compared to the SA-ACL group (3%, n=3). Although not significant (p=0.054), a similar 
trend was observed when comparing the SA-CON group (13%, n=12) to the SA-NON 
subgroup (11%, n=6). Furthermore, the genotype and allele frequency distributions 
significantly differed between the South African and Swedish cohorts (Supplementary Table 
6) for all the polymorphisms tested. Therefore, cohorts could not be combined for further 
analysis. 
 
Frequency distributions of allele combinations  
Allele combinations were inferred for COL5A1-IL1B-IL6 and COL5A1-IL1B-IL6R. For each of 
the two allele combinations, eight possible constructs were inferred at a frequency above 4%. 
For the South African cohort, no significant differences in the frequency distributions of these 
combinations were observed when all participants were evaluated or when only male or only 
female participants were compared (Supplementary Figure 2).  
 
The frequency distributions for the COL5A1-IL1B-IL6 and the COL5A1-IL1B-IL6R allele 
combinations were similar between the control and cases when all participants or only the 
female participants in the Swedish cohort were compared (Supplementary figures 3A and 
3C). However, for the COL5A1-IL1B-IL6 allele combination, when only males participants were 
evaluated, the T-C-G combination was significantly underrepresented (p=0.034 Haplo-score: 
2.1) in the SWE-CON (7.7%, n=3) compared to the SWE-NON (18.0%, n=8) group 
(Supplementary Figure 3B). Furthermore, the frequency distributions for the COL5A1-IL1B-
IL6R allele combinations, showed the T-C-A combination to be significantly underrepresented 
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(p=0.044, Haplo-score: 2.0) in the SWE-CON (28.0%, n=11) compared to the SWE-NON 
(14.0%, n=6) group when only the male participants were compared in the Swedish cohort.  
 
Discussion 
Considering the ligament as an integrative part of the knee joint, it is plausible that the ACL is 
subjected to cues derived from its surrounding anatomical structures, such as the synovium or 
synovial fluid. It is proposed, that as a response to repetitive mechanical overloading, 
macrophages might infiltrate tissues surrounding the ligaments27. Thereby, potentially exposes 
the ligamentocytes to an additional amount of specific inflammatory cytokines as part of the 
matrix remodeling mechanism. It is interesting, that some of the genetic susceptibility loci 
implicated in tendon and ligament injuries encode proteins involved in the homeostatic 
regulation of ECM components of both tendon and ligament, and components of the 
proinflammatory pathway2, 3. This study therefore, used a hypothesis-based approach to 
evaluate the potential impact of the inflammatory pathway on modulating susceptibility to 
ligament injuries using an in vitro risk associated model, complimented with a genetic 
association approach.  
For the functional IL1B rs16944 polymorphism, treatment with hrIL-β resulted in a 1.3-
fold decrease (p=0.020) of BGN and a 2.1-fold (p=0.012) decrease of COL5A1 in a genetic 
risk associated dependent manner. In addition, hrTNF-α treatment displayed a 2.0-fold 
(p=0.042) reduction in COL5A1 mRNA levels in the fibroblasts with an IL1B rs16944 CC 
genotype. We suggest that, given an inflammatory micro-environment where these cytokines 
are abundant, matrix production is differently affected in IL1B-high risk compared to IL1B-low 
risk genetic profiles.  
The IL6 rs1800795 G-allele increases IL-6 mRNA expression levels, inducing 
apoptosis15 which might decrease the production of ECM components. Our experiments 
indirectly support this hypothesis since fibroblasts having the IL6 rs1800795 GG genotype 
displayed a 2.8-fold reduction (p=0.012) in COL5A1 mRNA.  Although not significant, a similar 
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trend was observed for other associated ECM components such as DCN. This is an important 
finding, since both COL5A1 and DCN are required for normal fibrillogenesis28. 
 At basal levels, the expression of pro-inflammatory genes was relatively low for all 
groups. However, with the exception of TNFRSFA1 mRNA expression, mRNA levels of all the 
investigated cytokines were increased on average between 1.03 and 6109 fold in all the groups 
after treatment with hrIL-1β (Supplementary Figure 1C, D), hrIL-6 (Supplementary Figure 
1 E, F) and TNF-α (Supplementary Figure 1 G, H). More specifically, treatment with hrIL-1β 
significantly upregulated IL1B and IL6 mRNA levels 3690 and 3948 fold respectively, although 
no statistically significant differences in their expression were noted between the high- and 
low-risk groups. This is in agreement with the hypothesis as shown in Figure 1 and with 
previous work. 
These results support the proposal that polymorphisms within IL1B and IL6 alter the 
expression of structural and fibril-associated ECM components and herewith possibly 
modulate the susceptibility to ligament injuries. This holds true in specific cohorts where these 
loci were implicated in risk models for the susceptibility to tendon and ligament injuries13, 14. 
These associations were therefore evaluated in two independent population groups from 
different ancestries, one from Sweden and the other from South Africa in an attempt to identify 
the susceptibility significance of these genetic loci in different populations.    
In the South African cohort, the IL6R rs2228145 CC genotype was significantly 
overrepresented (p=0.028) in the controls, compared to individuals that sustained an ACL 
injury.  Although the CC genotype frequencies appeared to be similar in our Swedish cohort 
and in a previously reported South African Caucasian cohort13, it did not reach the level of 
significance. As shown previously, the COL5A1-IL1B-IL6 T-C-G and the COL5A1-IL1B-IL6R 
T-C-A allele combinations were found to be associated with an increased susceptibility to 
sustain an ACL rupture in the Swedish cohort when only male participants were evaluated13, 
14. These associations were not reproduced in the South African cohort evaluated in this study, 
which might be explained by the different genetic background of the cohorts, as illustrated by 
the significant differences in genotype frequencies.  
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 It becomes evident that a finely balanced inflammatory response is required for 
remodeling of the ECM29 and that genetic polymorphisms potentially affect the production of 
inflammatory cytokines12, 16. The specific identity of these biological key role players however 
still remain unknown, including the threshold number and the time course of when they are 
required to direct the remodeling process within tendon and ligament. Therefore, future 
research should focus on the identification and quantification of inflammatory factors and on 
their time courses in tendon and ligament injuries. This may provide insights for biology-based 
therapies, such as anti-cytokine antibodies or cytokine antagonists and the most effective 
treatment period. Another approach might be to target cells that are responsible for the 
production of inflammatory cytokines, such as macrophages.  
 The in vitro experiments used dermal fibroblasts of eight individuals. Although dermal 
fibroblasts might have similar characteristics as tenocytes or ligamentocytes, their function and 
exact composition differ, possibly influencing their response to stimuli. In addition, a tissue-
specific culture model applying a tensile force is required to study the effect of polymorphisms 
on matrix remodeling in more detail. Future research should aim to increase the number of 
donors. The difference in sex distribution in the genetic association study is explained by the 
fact that females participate less frequently in pivoting sports and therefore males and females 
were both tested together and separately for potential genetic associations with susceptibility 
for ACL injury. 
 In conclusion, this study describes specific polymorphisms within the inflammatory 
pathway to modulate the synthesis and degradation of structural and fibril-associated ECM 
components and thereby potentially contributing to an increased susceptibility to ACL injuries. 
This provisional evidence improves our understanding of the underlying mechanism for the 
genetic susceptibility to ACL ruptures and might lead to early identification of individuals who 
are of increased susceptibility to ACL injury and the potential application of personalized 
preventive or therapeutic interventions.  
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Practical implications 
- Given an inflammatory micro-environment where cytokines are abundant, 
matrix production is differentially affected in an IL1B genetic risk dependent 
manner 
- The work improves the understanding of how polymorphisms within the 
inflammatory signaling pathway modulate the susceptibility of ACL injuries 
- This knowledge contributes to the identification of potential therapeutic targets 
to reduce ACL injury and to enhance healing. 
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Table 1. Genotype and minor allele frequency distributions, and p-values for Hardy-
Weinberg exact test for the four selected polymorphisms in the control (SWE-CON and 
SA-CON), the anterior cruciate ligament (SA-ACL) rupture group and ACL subgroup 
with a noncontact (SWE-NON, and SA-NON) mechanism of injury within the South 
African and Swedish cohorts. 
 22 
  South Africa Sweden 
  SA-CON SA-ACL p-value1 SA-NON p-value2 SWE-CON SWE-NON p-value2 
 
 
COL5A1 
rs12722 
C > T 
n 96 93  48  109 77  
CC 37 (36) 27 (25) 0.866 35 (17) 0.793 22 (24) 23 (18) 0.773 
CT 49 (47) 52 (48)  54 (26)  43 (47) 47 (36)  
TT 14 (13) 22 (20)  10 (5)  35 (38) 30 (23)  
T allele 38 (73) 47 (88) 0.851 38 (36) 1.000 56 (123) 53 (82) 0.617 
HWE 0.829 0.824  0.367  0.241 0.648  
 
 
IL1B 
rs16944 
C > T 
n 98 93  48  112 78  
CC 24 (24) 27 (25) 0.530 27 (13) 0.923 39 (44) 44 (34) 0.799 
CT 47 (46) 52 (48)  44 (21)  41 (46) 40 (31)  
TT 29 (28) 22 (20)  29 (14)  20 (22) 17 (13)  
T allele 52 (102) 47 (88) 0.411 51 (49) 0.971 40 (90) 37 (57) 0.542 
HWE 0.549 0.836  0.395  0.120 0.224  
 
 
IL6  
rs1800795 
G > C 
n 98 98  51  113 77  
GG 72 (71) 64 (63) 0.445 67 (34) 0.339 22 (25) 26 (20) 0.606 
GC 26 (25) 31 (30)  27 (14)  59 (67) 52 (40)  
CC 2 (2) 5 (5)  6 (3)  19 (21) 22 (17)  
C allele 15 (29) 20 (40) 0.185 20 (20) 0.369 48 (109) 48 (74) 1.000 
HWE 1.000 0.539  0.373  0.060 0.821  
 
 
IL6R 
rs2228145 
A > C 
n 95 95  49  112 76  
AA 54 (51) 58 (55) 0.028 55 (27) 0.054 53 (59) 46 (35) 0.618 
AC 34 (32) 39 (37)  43 (21)  37 (41) 46 (35)  
CC 13 (12) 3 (3)  2 (1)  11 (12) 8 (6)  
C allele 29 (56) 23 (43) 0.161 23 (23) 0.346 29 (65) 31 (47) 0.779 
HWE 0.082 0.385  0.257  0.253 0.599  
 23 
Genotype and allele frequencies are expressed as a percentage with the number of 
participants (n) in parentheses. 1 CON vs. ACL (unadjusted p-value), 2 CON vs. NON 
(unadjusted p-value). P-values in bold typeset indicate significance (p< 0.050) 
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Figure 1: Schematic representation of the proposed downstream effects of cytokines 
IL-1β and IL-6 which are upregulated in response to mechanical loading of a ligament 
13-15, 30 
Activation/upregulation is represented by a pointed arrow head (→) and inhibition/down 
regulation is represented by a perpendicular line at the end (      ). The boxed molecules are 
the ones investigated in the current study. Abbreviations: ECM, extracellular matrix; IL-1β, 
interleukin-1β; IL-6, interleukin-6; IL-6R, interleukin-6 receptor; MMPs, matrix 
metallaproteinases; ROS, reactive oxygen species; TGF-β, transforming growth factor β; 
TNF-α, tumor necrosis factor
Figure 2: mRNA expression of extracellular matrix genes in stimulated and unstimulated 
fibroblasts. Primary human fibroblasts were obtained from 8 healthy volunteers and classified 
in high risk or low risk for ligament injuries based on IL1B rs12722 C>T (A, C, E, G) and IL6 
rs1800795 G>C (B, D, F, H). Fibroblasts were treated with vehicle (PBS) to evaluate basal 
levels (A, B)  or hr-IL-6 (C, D), hrIL-1β (E, F) or hrTNF-α (G, H) to evaluate fold-response to 
the treatment, compared to vehicle of the expression of extracellular matrix genes type I 
collagen α1 (COL1A1), type V collagen α1 (COL5A1), decorin (DCN), biglycan (BGN). Data is 
presented as (A, B) 2-ΔCt to assess gene expression compared to CFL1 (housekeeping gene) 
or (C-H) fold to vehicle (dotted lines). Data is presented as mean with standard deviation (SD). 
Unpaired two-tailed Student’s t- test. P-values in bold typeset indicate significance (p< 0.050) 
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Figure 1  
Supplementary Table 1. Primers used for RT-PCR analysis 
 
Gene Forward primer (5’  3’) Reverse primer (5’  3’) 
COL5A1 GACAAGAAGTCCGAAGGGGC TAGGAGAGCAGTTTCCCACG 
COL1A1 TGAAGGGACACAGAGGTTTCAG GTAGCACCATCATTTCCACGA 
DCN CAGACCAAGCACGCAAAACA TCACAACCAGGGAACCTTGC 
BGN CACCGGACAGATAGACGTGC CATGGCGGATGGACCTGGAG 
IL6 GGATTCAATGAGGAGACTTGCC GGGTCAGGGGTGGTTATTGC 
IL1B TTGCTCAAGTGTCTGAAGCAGC CTTGCTGTAGTGGTGGTCGG 
IL6R CACGCCTTGGACAGAATCCA TCCAGCAACCAGGAATGTGG 
IL1R1 GGTAGACGCACCCTCTGAAG GCATTTATCAGCCTCCAGAGAAGA 
TNFRSFA1 ATTGGACTGGTCCCTCACCT GTAGGTTCCTTTGTGGCACTT 
CFL1 ATAAGGACTGCCGCTATGCC CGGGGGCCCAGAAGATAAAC 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 2. Genetic risk profiles of the participants based on their (A) IL1B rs16944 C>T and (B) IL6 rs1800795 
G>C genotypes. 
A.               B. 
 Participant 
ID 
IL1B 
rs16944 
Sex   Participant ID 
IL6 
rs1800795 
Sex 
Low 
risk 
5 CT F  
Low 
risk 
3 CC M 
7 CT M  5 GC F 
8 CT F  22 GC M 
11 CT M  24 GC F 
22 TT M  
High 
risk 
7 GG M 
High 
risk 
3 CC M  8 GG F 
10 CC M  10 GG M 
24 CC F  11 GG M 
 
M, male; F, female 
 
 
 
 
 
 
Supplementary Table 3. Patient characteristics of the control (SWE-CON) group and the anterior cruciate ligament group 
with a noncontact (SWE-NON) mechanism of injury in a Swedish cohort 
 SWE-CON (n=116) SWE-NON (n=79) p-value 
Age (years)1 44.7 ± 11.9 (114) 36.5 ± 13.7 (78) <0.001 
Sex (% male) 34.5 (116) 54.4 (79) 0.014 
Height (cm) 172.3 ± 10.1 (108) 173.4 ± 8.6 (71) 0.438 
Body mass (kg)1 72.1 ± 13.6 (107) 75.0 ± 12.8 (71) 0.149 
Body mass index (kg/m2)1 24.4 ± 2.9 (107) 24.7 ± 2.9 (70) 0.466 
Values are presented as mean ± standard deviations except for sex, which is expressed as a percentage. The number of participants 
(n) with available data for each variable is in parenthesis. 
1Self-reported values at the time of recruitment for the SWE-CON group, and at time of ACL rupture for the SWE-NON group. 
 
 
 
 
 
 
 
Supplementary Table 4. Medical history and family injury for the control (SWE-CON) and non-contact (SWE-NON) anterior 
cruciate ligament rupture group of the Swedish cohort 
 Male Female  
 SWE-
CON  
(n= 40) 
SWE-
NON  
(n= 42) 
p-value1 SWE-
CON  
(n= 76) 
SWE-
NON  
(n= 37) 
p-value1 p-value2 
Previous ligament 
injury 
88.6 (35) 100.0 
(35) 
0.114 73.5 (68) 81.8 (33) 0.458 0.035 
Previous joint injury 35.1 (37) 51.3 (39) 0.235 37.5 (72) 41.7 (36) 0.834 0.230 
Family history of 
ACL injury 
• Grandparent 
• Parent 
• Sibling 
• Child 
• Other 
 
15.2 (33) 
0.0 (33) 
0.0 (33) 
12.1 (33) 
3.0 (33) 
0.0 (33) 
 
24.3 (37) 
0.0 (37) 
2.7 (37) 
10.8 (37) 
10.8 (37) 
0.0 (37) 
 
0.384 
- 
1.000 
1.000 
0.361 
- 
 
17.4 (69) 
0.0 (69) 
7.2 (69) 
2.9 (69) 
7.2 (69) 
0.0 (69) 
 
33.3 (33) 
3.0 (33) 
12.1 (33) 
6.1 (33) 
6.1 (33) 
6.1 (33) 
 
0.121 
0.323 
0.466 
0.593 
1.000 
0.103 
 
0.093 
0.407 
0.531 
0.551 
0.551 
0.164 
Family history of 
joint injury 
• Parent 
• Sibling 
• Child 
 
59.5 (37) 
21.6 (37) 
43.2 (37) 
27.0 (37) 
 
69.2 (39) 
46.2 (39) 
48.7 (39) 
17.9 (39) 
 
0.516 
0.031 
0.804 
0.415 
 
47.2 (72) 
31.9 (72) 
15.3 (72) 
20.8 (72) 
 
72.2 (36) 
47.2 (36) 
44.4 (36) 
19.4 (36) 
 
0.024 
0.181 
0.002 
1.000 
 
0.014 
0.018 
0.003 
0.608 
Values are expressed as percentages with the number of participants (n) with available data in parentheses.  
1 SWE-CON vs. SWE -NON, p-values in bold typeset indicate significance (p< 0.050) 
2 SWE-CON (male + female) vs. SWE-NON (male + female), p-values in bold typeset indicate significance (p< 0.050)    
Supplementary Table 5. Genotype effects per patient characteristic in the Swedish cohort 
 
A. Genotype effects COL5A1 rs2228145 C>T 
 C/C (n= 42) C/T (n= 83) T/T (n= 61) p-value 
Age (years) 40.2 ± 12.6 (40) 39.9 ± 13.2 (83) 44.0 ± 13.5 (60) 0.145 
Sex (% male) 50.0 (21) 43.3 (36) 34.4 (21) 0.197 
Height (cm) 174.7 ± 11.0 
(38) 
172.1 ± 9.0 (78) 171.9 ± 8.6 (55) 0.308 
Body mass (kg) 74.1 ± 11.8 (38) 77.3 ± 13.8 (77) 73.3 ± 13.2 (55) 0.782 
Body mass index (kg/m2) 24.0 ± 2.7 (37) 24.6 ± 2.8 (77) 24.7 ± 3.1 (55) 0.536 
 
B. Genotype effects IL1B rs16944 C>T 
 C/C (n= 78) C/T (n= 77) T/T (n= 35) p-value 
Age (years) 42.2 ± 13.2 (77) 39.8 ± 13.3 (75) 42.2 ± 13.5 (35) 0.483 
Sex (% male) 50.0 (39) 31.1 (24) 48.6 (17) 0.091 
Height (cm) 173.8 ± 9.3 (72) 171.2 ± 9.1 (72) 173.7 ± 9.5 (30) 0.203 
Body mass (kg) 75.7 ± 12.2 (70) 71.6 ± 12.8 (72) 73.0 ± 16.0 (31) 0.172 
Body mass index (kg/m2) 24.9 ± 2.8 (70) 24.3 ± 2.7 (72) 24.7 ± 3.2 (30) 0.360 
 
C. Genotype effects IL6 rs1800795 G>C 
 C/C (n= 45) C/G (n= 107) G/G (n= 38) p-value 
Age (years) 44.8 ± 12.5 (38) 40.8 ± 13.7 (104) 40.2 ± 12.7 (45) 0.211 
Sex (% male) 47.4 (18) 37.4 (40) 46.7 (21) 0.536 
Height (cm) 172.7 ± 8.3 (36) 172.3 ± 9.7 (96) 173.0 ± 9.7 (43) 0.927 
Body mass (kg) 73.1 ± 11.5 (72) 73.5 ± 14.6 (96) 73.1 ± 12.1 (43) 0.983 
Body mass index (kg/m2) 24.5 ± 2.6 (35) 24.7 ± 3.0 (95) 24.3 ± 2.7 (43) 0.679 
 
 
 
D. Genotype effects IL6R rs2228145 A>C 
 A/A (n= 94) A/C (n = 76) C/C (n = 18) p-value 
Age (years) 41.4 ± 13.2 (93) 40.9 ± 14.2 (75) 42.9 ± 8.0 (17) 0.850 
Sex (% male) 42.6 (40) 36.8 (28) 55.6 (10) 0.882 
Height (cm) 172.2 ± 9.7 (84) 172.5 ± 8.6 (70) 174.6 ± 9.6 (18) 0.610 
Body mass (kg) 72.4 ± 11.7 (85) 73.5 ± 14.4 (69) 75.4 ± 12.4 (17) 0.653 
Body mass index (kg/m2) 24.2 ± 2.6 (84) 24.8 ± 3.0 (69) 24.7 ± 2.6 (17) 0.407  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Supplementary Table 6. Genotype and minor allele frequency distributions, and p-values for Hardy-Weinberg exact test of 
the four selected polymorphisms within the South African (SA) and Swedish (SWE) cohort for asymptomatic controls 
(CON), the anterior cruciate ligament (ACL) rupture group and the ACL subgroup with a noncontact (NON) mechanism. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  CON ACL 
  SA-CON SWE-CON P-value1 SA -ACL SWE -ACL P-value1 SA -NON P-value2 
 
 
COL5A1 
rs12722 
C > T 
n 96 109  93 71  48  
CC 38 (36) 22 (24) <0.001 41 (38) 23 (18) 0.019 35 (17) 0.021 
CT 49 (47) 43 (47)  45 (42) 47 (36)  54 (26)  
TT 14 (13) 35 (38)  14 (13) 30 (23)  10 (5)  
T allele 38 (73) 56 (123) <0.001 37 (68) 53 (82) 0.003 38 (36) 0.022 
HWE 0.829 0.241  0.824 0.648  0.367  
 
 
IL1B 
rs16944 
C > T 
n 93 112  93 78  48  
CC 24 (24) 39 (44) 0.033 27 (25) 44 (34) 0.033 27 (13) 0.095 
CT 47 (46) 41 (46)  52 (48) 40 (31)  44 (21)  
TT 29 (28) 20 (22)  22 (20) 17 (13)  29 (14)  
T allele 52 (102) 40 (90) 0.019 47 (88) 37 (57) 0.058 51 (49) 0.033 
HWE 0.549 0.120  0.836 0.224  0.395  
 
 
IL6  
rs1800795 
G > C 
n 98 113  98 77  51  
GG 72 (71) 22 (25) <0.001 64 (63) 26 (20) <0.001 67 (34) <0.001 
GC 26 (25) 59 (67)  31 (30) 52 (40)  27 (14)  
CC 2 (2) 19 (21)  5 (5) 22 (17)  6 (3)  
C allele 15 (29) 48 (109) <0.001 20 (40) 48 (74) <0.001 20 (20) <0.001 
HWE 1.000 0.061  0.539 0.821  0.373  
 
 
IL6R 
rs2228145 
A > C 
n 112 95  76 95  49  
AA 53 (59) 54 (51) 0.996 46 (35) 58 (55) 0.165 55 (27) 0.886 
AC 37 (41) 34 (32)  46 (35) 39 (37)  43 (21)  
CC 11 (12) 13 (12)  8 (6) 3 (3)  2 (1)  
C allele 29 (65) 29 (56) 1.000 31 (47) 23 (43) 0.108 23 (23) 0.256 
HWE 0.082 0.253  0.385 0.599  0.257  
Genotype and allele frequencies are expressed as a percentage with the number of participants (n) in parentheses.  
1 SA vs. SWE cohort (unadjusted p-value), 2 SA with non-contact mechanism vs. SWE cohort (unadjusted p-value), P-values in bold 
typeset indicate significance (p< 0.050) 
A.       B. 
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Supplementary Figure 1: mRNA expression in unstimulated fibroblasts (A, B) 
and fibroblasts stimulated with IL-1β (C, D), IL-6 (E, F) or TNF-α (G, H). mRNA 
expression levels of the cytokine-related genes, IL6, IL1B, IL6R, IL1R1 and 
TNFRSF1AR in fibroblasts classified in high-risk or low-risk for ACL injuries based on 
(A) IL6 rs1800795 G>C or (B) IL1B rs12722 C>T. Data is presented as 2-ΔCt to 
assess gene expression compared to CFL1 (housekeeping gene). Data is presented 
as mean with standard deviation (SD). Unpaired two-tailed Student’s t-test, P-values 
in bold represent p-alue 
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A. All participants (males and females), 
 
 
 
 
 
 
 
 
 
 
 
 
B. Male participants 
 
 
 
 
 
 
 
 
 
 
 
C. Female participants           
 
 
Supplementary Figure 2: Frequency distributions in the South African cohort for 
the COL5A1 rs12722 C>T, IL1B rs16944 C>T, IL6 rs1800795 G>C or IL6R 
rs2228145 A>C polymorphisms in the control group (CON; black bars) and the 
anterior cruciate ligament rupture group (ACL; white bars) for (A) all participants 
(males and females), (B) the male participants and (C) female participants. The 
number of participants (n) in each group is in parentheses
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A. All participants (males and females)       
B. Male participants      
 
C. Female participants 
 
 
 
 
 
 
Supplementary Figure 3: Frequency distributions in the Swedish (SWE) cohort 
for the COL5A1 rs12722 C>T, IL1B rs16944 C>T, IL6 rs1800795 G>C or IL6R 
rs2228145 A>C polymorphisms in the control group (SWE-CON; black bars) and 
the non-contact anterior cruciate ligament rupture group (SWE-NON; white bars) 
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for (A) all participants (males and females), (B) male participants and (C) female 
participants in the Swedish cohort. The number of participants (n) in each group is 
in parentheses. P-values in bold typeset indicate significance (p< 0.050)  
A.       B. 
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